Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1

HIV Therapy

Volumn 3, Issue 1, 2009, Pages 63-77

  Rossotti, Roberto ^a   Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Drug resistance; Genetic barrier; HIV 1; Non nucleoside reverse transcriptase inhibitor; Viral evolution

Indexed keywords

5 [3,5 DIETHYL 1 (2 HYDROXYETHYL) 4 PYRAZOLYLOXY] 1,3 BENZENEDINITRILE; ATAZANAVIR; BENZOPHENONE DERIVATIVE; BILR 355BS; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; GW 4511; GW 678248; GW 678284; GW 695634; IDX 899; INDAZOLE DERIVATIVE; MK 1107; MK 4965; NEVIRAPINE; PLACEBO; PROTEINASE INHIBITOR; RDEA 806; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RO 5028; UNCLASSIFIED DRUG; ZIDOVUDINE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MORNING DOSAGE; NONHUMAN; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 67149086037     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/17584310.3.1.63     Document Type: Review

References (80)

1. Mitsuya H, Yarchoan R, Broder S: Molecular target for AIDS therapy. Science 249, 1533-1544 (1990).
2. Pauwels R, Andries K, Desmyter J et al.: Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470-474 (1990).
3. Huang H, Chopra R, Verdine GL et al.: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-1675 (1998).
4. Kohlstaedt LA, Wang J, Friedman JM et al.: Crystal structure at 35 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
5. Ren J, Stammers DK: Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 134, 157-170 (2008). ■■ Describes the mechanisms of non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance, including updated crystallographic and other biochemical analyses.
6. De Clercq E: New developments in anti-HIV chemotherapy. Curr. Med. Chem. 8, 1543-1572 (2001).
7. Johnson VA, Brun-Vezinet F, Clotet B et al.: Update of the drug resistance mutations in HIV-1: Spring 2008. Top. HIV Med. 16, 62-68 (2008).
8. Esnouf R, Ren J, Ross C et al.: Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2, 303-308 (1995).
9. De Clercq: E HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47, 155-169 (1994).
10. Maga G, Amacker M, Ruel N et al.: Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274, 738-747 (1997).
11. Rodriguez-Barrios F, Gago F: Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. J. Am. Chem. Soc. 126, 15386-15387 (2004).
12. Das K, Clark AD Jr, Lewi PJ et al.: Roles of conformational and positional adaptability in structure based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47, 2550-2560 (2004).
13. Chan JH, Freeman GA, Tidwell JH et al.: Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 47, 1175-1182 (2004).
14. Stammers DK, Stuart DI, Ren J et al.: Structural studies of benzophenone/HIV-1 RT complexes: insights into the potency of the next generation NNRTIs against WT and mutant HIV-1. Antivir. Ther. 9, S36 (2004).
15. Ren J, Nichols CE, Chamberlain PP et al.: Crystal structures of HIV-1 reverse transcriptase mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. 336, 569-578 (2004).
16. Schweighardt B, Ortiz GM, Grant RM et al.: Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 16, 2342-2344 (2002).
17. Domaoal RA, Demeter LM: Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int. J. Biochem. Cell Biol. 36, 1735-1751 (2004). ■ Interesting review describes the in vivo and in vitro effects of mutations selected by first-generation NNRTIs.
18. Bacheler LT, Anton ED, Kudish P et al.: Human immunodeficiency virus type-1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44, 2475-2484 (2000).
19. Richman DD, Havlir D, Corbeil J et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68, 1660-1666 (1994).
20. Olmsted RA, Slade DE, Kopta LA et al.: (Alkylamino) piperidine bis(heteroaryl) piperizine analogs are potent, broad-spectrum non nucleoside reverse transcriptase inhibitors of drug resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. J. Virol. 70, 3698-3705 (1996).
21. Kleim JP, Bender R, Bilhardt UM et al.: Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37, 1659-1664 (1993).
22. Hsiu Y, Das K, Ding J et al.: Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 284, 313-323 (1998).
23. Figueiredo A, Zelina S, Sluis-Cremer N et al.: Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. Curr. HIV Res. 6(2), 130-137 (2008).
24. Hizi A, Tal R, Shaharabany M et al.: Catalytic properties of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem. 266, 6230-6239 (1991).
25. Ren J, Bird LE, Chamberlain PP et al.: Structure of HIV-2 reverse transcriptase at 2.35-Å resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl Acad. Sci. USA 99(22), 14410-14415 (2002). ■ Few data are available regarding the HIV-2 molecular structure and its diversity compared with HIV-1. This paper, although not so recent, provides some interesting insights into the crystallographic structure of HIV-2 reverse transcriptase.
26. Ren J, Diprose J, Warren RM et al.: Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses. J. Biol. Chem. 275, 5633-5639 (2000).
27. Auwerx J, Stevens M, Van Rompay AR et al.: The phenylethylthiazolylthiourea nonnucleoside reverse transcriptase (RT) inhibitor MSK-076 selects for a resistance mutation in the active site of human immunodeficiency virus type-2 RT. J. Virol. 78 (14), 7427-7437 (2004).
28. Zhang Z, Hamatake R, Hong Z: Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir. Chem. Chemother. 15, 121-134 (2004).
29. Temiz NA, Bahar I: Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. Proteins 49, 61-70 (2002).
30. Udier-Blagovic M, Tirado-Rives J, Jorgensen WL: Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. J. Am. Chem. Soc. 125, 6016-6017 (2003).
31. Ren J, Milton J, Weaver KL et al.: Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Struct. Fold Des. 8, 1089-1094 (2000).
32. Piscitelli S, Baede P, DeDier K et al.: Pharmacokinetics of TMC125 in HIV-infected patients and healthy volunteers. Presented at: 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington DC, WA, USA, 13 April 2002.
33. Gazzard BG, Pozniak AL, Rosenbaum W et al.: An open-label assessment of TMC125: a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17, F49-F54 (2003).
34. The TMC125-C223 Writing Group: efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24 week analysis. AIDS 21, F1-F10 (2007).
35. Madruga JV, Cahn P, Grinzstejn B et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1, 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370, 29-38 (2007). ■ Along with [36], describes the most important studies that led to the US FDA approval of etravirine and provide useful information about several aspects of TMC125.
36. Lazzarin A, Campbell T, Clotet B et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2, 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370, 39-48 (2007). ■ Along with [35], describes the most important studies that led to the FDA approval of etravirine and provide useful information about several aspects of TMC125.
37. Haubrich R, Cahn P, Grinsztejn B et al.: DUET-1: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 versus placebo in 612 treatment-experienced HIV-1-infected patients. Presented at: 15th conference on retroviruses and opportunistic infections. Boston, MA, USA, 3-6 February 2008.
38. Johnson M, Campbell T, Clotet B et al.: DUET-2: week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of tmc125 vs placebo in 591 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
39. Ruxrungtham K, Pedro RJ, Latiff GH et al.: Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med. 9, 883-896 (2008).
40. Cahn P, Haubrich R, Leider J et al.: Pooled 24-week results of DUET-1 and -2: TMC125 (etravirine; ETR) versus placebo in 1203 treatment-experienced HIV-1-infected patients. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
41. Vingerhoets J, Peters M, Azijn H et al.: An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir. Ther. 13(Suppl. 3), A26 (2008). ■ Represents the most up-to-date study on etravirine resistance-associated mutations.
42. Coakley E, Chappey C, Benhamida J et al.: Biological and clinical cut-off analyses for etravirine in the Phenosense™ HIV assay. Antivir. Ther. 13(Suppl. 3), A134 (2008).
43. Peeters M, Nijs S, Vingerhoets J et al.: Determination of phenotypic clinical cut-offs for etravirine: pooled week 24 results of the DUET-1 and DUET-2 trials. Antivir. Ther. 13(Suppl. 3), A133 (2008).
44. Benhamida J, Chappey C, Coakley E et al.: HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Antivir. Ther. 13(Suppl. 3), A142 (2008).
45. Bacheler LT, Anton ED, Kudosh P et al.: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44(9), 2475-2484 (2008).
46. MacArthur RD, Kosmyna JM, Crane LR et al.: The presence or absence of zidovudine in a nevirapine-containing antiviral regimen determines which of two nevirapine-mutations occurs on virologic failure. Presented at: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 26-29 September 1999.
47. MacArthur RD, Huppler Hullsiek K, Peng G et al.: Failing therapy with efavirenz results in significantly fewer mutations limiting to etravirine than failing therapy with nevirapine: on-treatment analyses from the CPCRA first study. Presented at: XVII International HIV Drug Resistance Workshop. Sitges, Spain 10-14 June 2008.
48. Di Vincenzo P, Rusconi S, Adorni F et al.: Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). Presented at: 6th European HIV Drug Resistance Workshop. Budapest, Hungary, 26-28 March 2008.
49. Lapadula G, Calabrese A, Castelnuovo F et al.: Prevalence and risk factors for etravirine resistance among patients failing to non-nucleoside reverse transcriptase inhibitors. Antivir. Ther. 13(4), 601-605 (2008).
50. Guillemont J, Pasquier E, Palandjian P et al.: Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J. Med. Chem. 48, 2072-2079 (2005).
51. Janssen PA, Lewi PJ, Arnold E et al.: In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl] 2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile (R278474, Rilpivirine). J. Med. Chem. 48, 1901-1909 (2005).
52. Lewi PJ, de Jonge M, Daeyaert F et al.: On the detection of multiple-binding modes of ligands to proteins, from biological, structural and modeling data. J. Comput. Aided Mol. Des. 17, 129-134 (2003).
53. Das K, Bauman JD, Clark AD Jr et al.: High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc. Natl Acad. Sci. USA 105(5), 1466-1471 (2008).
54. Cheung PK, Wynhoven B, Harrigan PR: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev. 6, 107-116 (2004).
55. Goebel F, Yakovlev A, Pozniak AL et al.: Short-term antiviral activity of TMC278: a novel NNRTI - in treatment-naive HIV-1 infected subjects. AIDS 20, 1721-1726 (2006).
56. Santoscoy M, Cahn P, Gonsalez C et al.: TMC278 (rilpivirine), a next-generation NNRTI, demonstrates long-term efficacy and tolerability in ARV-naive patients: 96 weeks results of study C204. Presented at: 17th International AIDS Conference. Mexico City, Mexico, 3-8 August 2008. ■ TMC278 is a highly promising antiretroviral owing to its strong potency and high genetic barrier to resistance. This paper highlights some of the latest available data on this drug.
57. Crauwels H, van Heeswijk R, Kestens D et al.: The pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). Presented at: 17th International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.
58. Jakubik J, Seifer M, Gray L et al.: IDX12899 anti-HIV-1 activity and resistance profile is superior to efavirenz. Antivir. Ther. 12(Suppl. 1), S32 (2007).
59. Jakubik JJ, Chapron C, Hubbard L et al.: In vitro cross-resistance profile for a next-generation non-nucleoside reverse transcriptase inhibitor: IDX899. Antivir. Ther. 13(Suppl. 3), A28 (2008). ■ Although only in vitro data are presented here, the paper describes the cross-resistance mutations among currently available, in-development NNRTIs and this new molecule, IDX899.
60. Zala C, Murphy R, Zhou XJ et al.: IDX899, a novel HIV-1 NNRTI with high barrier to resistance, provides suppression of HIV viral load in treatment-naive HIV-1-infected subjects. Presented at: 17th International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.
61. Zhou XJ, Pietropaolo K, Belanger B et al.: Pharmacokinetic drug-drug interaction between IDX899 and Atazanavir. Presented at: 17th International AIDS Conference. Mexico City, Mexico, 3-8 August 2008.
62. De La Rosa M, Kim HW, Gunic E et al.: Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 16 (17), 4444-4449 (2006).
63. Hamatake R, Zhang Z, Bellows D et al.: RDEA806, a potent NNRTI with a high genetic barrier to resistance. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
64. Moyle G, Boffito M, Manhard K et al.: Antiviral activity of RDEA806, a novel non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients. Presented at: 17th International AIDS Conference. Mexico City, Mexico, 3-8 August 2008. ■ This molecule is in early development phases and few data are available. This paper from the latest International AIDS Society conference summarizes new evidence on its antiviral profile.
65. Javanbakht H, Li Y, Sweeney Z et al.: In vitro selection and characterization of viruses resistant to RO-5028, a novel non-nucleoside reverse transcriptase inhibitor. Antivir. Ther. 13(Suppl. 3), A23 (2008).
66. Klumpp K, Dunn J, Su G et al.: Preclinical profile of R7180, a prodrug of the novel NNRTI RO-5028, with high antiviral potency against wild-type and NNRTI-resistant viruses. Antivir. Ther. 13(Suppl. 3), A29 (2008). ■ Few data are available on this drug. This paper covers the development of the molecule so far.
67. Mori J, Corbau R, Lewis D et al.: In vitro characterization of UK-453,061, a non-nucleoside reverse transcriptase inhibitor. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
68. Corbau R, Allan G, Burt C et al.: UK-453,061: a non-nucleoside reverse transcriptase inhibitor for the treatment of drug-resistant HIV infections. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007.
69. Fatkenheuer G, Staszewski S, Plettenburg A et al.: Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV-infected patients. Presented at: 3rd International AIDS Society Conference. Sydney, Australia, 22-25 July 2007. ■ This work shows the first, though limited, clinical data on in vivo use of UK-453,061.
70. Coulombe R, Fink D, Landry S et al.: Crystallographic study with BILR 355 BS, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. Presented at: 3rd International AIDS Society Conference. Rio de Janeiro, Brazil, 24-27 July 2005.
71. Bonneau P, Robinson P, Duan J et al.: Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor with a broad anti HIV-1 profile. Presented at: 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22-25 February 2005.
72. Huang F, Koenen-Bergmann M, MacGregor TR et al.: Pharmacokinetic and safety evaluation of BILR355, a second generation non-nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 52(12), 4300-4307 (2008). ■ This paper represents the most recent data about BILR 355 BS; since pharmacokinetic characteristics of BILR 355 BS appear to be its main drawback factor; the paper provides comprehensive information on this matter.
73. Chen M, Ma L, Drusano GL et al.: Sex differences in CYP3A activity using intravenous and oral midazolam. Clin. Pharmacol. Ther. 80, 531-538 (2006).
74. Bonneau PR, Robinson PA, Lie Y et al.: BILR 355: new NNRTI. Antivir. Ther. 10(Suppl. 1), S81 (2005).
75. Tucker TJ, Sisko JT, Tynebor RM et al.: Discovery of 3-{5-[(6-amino-1Hpyrazolo [3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5- chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J. Med. Chem. 51, 6503-6511 (2008).
76. Dykes C, Demeter LM: Y188H, which is a potential intermediate between wild-type (WT) and Y188L, has markedly reduced replication efficiency. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007.
77. Chan JH, Freeman GA, Tidwell JH et al.: Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. 47 (5), 1175-1182 (2004).
78. Romines KR, Freeman GA, Schaller LT et al.: Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. J. Med. Chem. 79 (2), 727-739 (2006).
79. Ferris RG, Hazen RJ, Roberts GB et al.: Antiviral activity of GW678248, a novel benzophenone nonucleoside reverse transcriptase inhibitor. Antimicrob. Agents Chemother. 49 (10), 4046-4051 (2005).
80. Sweeney ZK, Dunn JP, Li Y et al.: Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 18, 4352-4354 (2008).